Work ability: a new outcome measure in rheumatoid arthritis?

Raterman, Hennie G.; Hoving, Jan L.; Nurmohamed, Michael T.; Herenius, M M J; Sluiter, Judith K.; Lems, Willem F.; Tak, Paul‐Peter; Dijkmans, Ben A. C.; Twisk, Jos W. R.; Frings‐Dresen, Monique H. W.; Voskuyl, Alexandre E.

doi:10.3109/03009740903447044

Cited by 23 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result conforms with the findings of Pollard et al 22 and Raterman et al 29 which confirm that fatigue has a negative impact on disease activity in patients with RA.…”

Section: 21supporting

confidence: 92%

Disease Activity (Rheumatoid Arthritis Disease Activity Index-5) in Patients With Rheumatoid Arthritis and its Association With Quality of Life, Pain, Fatigue, and Functional and Psychological Status

Sunar

2015

Arch Rheumatol

View full text Add to dashboard Cite

Objectives: This study aims to determine disease activity in patients with rheumatoid arthritis by Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), and to evaluate its association with the quality of life, pain, fatigue, and functional and psychological status. Patients and methods: A total of 170 rheumatoid arthritis patients (30 males, 140 females; mean age 55.2±11.3 years; range 28 to 82 years) were included in the study. Quality of life was evaluated by using Rheumatoid Arthritis Quality of Life Scale. Stanford Health Assessment Questionnaire was used for evaluating functional status, and Beck Depression Scale for psychological status. Level of fatigue was assessed by Fatigue Severity Scale. Disease activity was measured by using Disease Activity Score-28 (DAS28) and RADAI-5. Results: Mean RADAI-5 score was 3.9±2.7, and mean DAS28 score was 3.3±1.4 (moderate disease activity). According to 16.5% of the patients were in remission, 28% had mild disease activity, 27% had moderate disease activity, and 29% had high disease activity. RADAI-5 was strongly correlated with visual analog scale-pain, DAS28, Beck Depression Scale, Fatigue Severity Scale, Rheumatoid Arthritis Quality of Life Scale, and Health Assessment Questionnaire (r= 0.91, 0.81, 0.78, 0.75, 0.75 and 0.72, respectively) (p<0.0001). Disease activity values measured with RADAI-5 were compatible with the ones measured with DAS28. Conclusion: RADAI-5 is a short, practical questionnaire that can easily be administered by the patient in a busy clinical practice setting. It can be used as a rheumatoid arthritis outcome measure to estimate the impact of the disease and evaluate health outcome in clinical studies.

show abstract

“…This result conforms with the findings of Pollard et al 22 and Raterman et al 29 which confirm that fatigue has a negative impact on disease activity in patients with RA.…”

Section: 21supporting

confidence: 92%

Disease Activity (Rheumatoid Arthritis Disease Activity Index-5) in Patients With Rheumatoid Arthritis and its Association With Quality of Life, Pain, Fatigue, and Functional and Psychological Status

Sunar

2015

Arch Rheumatol

View full text Add to dashboard Cite

show abstract

“…18 Studies on the effects of TNF antagonists on work limitations in RA patients have had either a retrospective observational design or a clinical primary outcome with work data examined as a secondary outcome. [19][20][21][22][23][24] These studies show an improvement in employability and a reduction in the workday losses in patients with RA and ankylosing spondylitis through the treatment with biologics (TNF antagonists). 17,23,25 In the present study, we examined the correlation between changes in work productivity and disease activity.…”

Section: Discussionmentioning

confidence: 99%

Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis

Furuya

Kasama

Isozaki³

et al. 2013

JMDH

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a significant cause of work disability and job loss. The resulting economic burden experienced by patients has received considerable research attention. This research assesses the effect of tumor necrosis factor (TNF) antagonists (infliximab, etanercept) on the ability of RA patients living in Japan to work and participate in society. A total of 42 patients with active RA were enrolled and given biological therapy for 12 months (mo). Of these patients, 14 were employed full-time, 6 were employed part-time, and 22 were not employed. Twenty-six patients were given infliximab, and sixteen were given etanercept. The amount of domestic labor performed before the biologics served as a baseline and was assigned a value of 0%. After treatment with biologics, the productivity was evaluated using the visual analog scale (VAS; -100 to +100 mm). The administration of TNF antagonists to RA patients who exhibited an insufficient response to medical treatment significantly improved the Disease Activity Score 28 (DAS 28) after both 6 mo and 12 mo (P , 0.0001). A significant correlation was found between the improvement in their DAS 28 and improvements in their work situation (Productivity VAS) (P , 0.05). Of particular interest is the significant correlation between the values of baseline mHAQ and the percent changes of Productivity VAS that was observed after 6 mo and 12 mo (P , 0.05). Our findings indicate that medical treatment of RA with TNF antagonists improves the patients' ability to perform their jobs and housekeeping. Because loss of productivity is an important contributor to the indirect costs of RA, our findings are relevant for the pharmacoeconomic assessment of treatments.

show abstract

“…In addition to early treatment, combination treatment with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), and biologic DMARDs, such as those targeting tumor necrosis factor-α (TNF-α; infliximab, etanercept, and adalimumab [ADA; AbbVie Inc., North Chicago, IL, USA]), interleukin-6 (IL-6; tocilizumab), IL-1 (anakinra), or T cells (abatacept) provide favorable short- and long-term outcomes [13, 14]. Results of multiple studies (including several conducted in Japan) also indicate that TNF-α inhibitors such as etanercept and infliximab improve patients’ employability and ability to perform work and housekeeping tasks [4, 15–20]. …”

Section: Introductionmentioning

confidence: 99%

Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study

et al. 2017

View full text Add to dashboard Cite

IntroductionThe Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan.MethodsPatients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness.ResultsOf the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI/RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs (p < 0.05). Additionally, remission rates (according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores) and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups (p < 0.0001). Analysis of patient subgroups revealed better WPAI/RA outcomes for patients who were biologic-naïve, treated with concomitant methotrexate, or with RA duration of ≤2 years (p < 0.05). The rate of serious adverse events over 48 weeks of ADA treatment was 5.23%.ConclusionsTreatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA.FundingAbbVie GK and Eisai Co., Ltd.Trial RegistrationClinicalTrials.gov identifier, NCT01346488.

show abstract

Work ability: a new outcome measure in rheumatoid arthritis?

Cited by 23 publications

References 28 publications

Disease Activity (Rheumatoid Arthritis Disease Activity Index-5) in Patients With Rheumatoid Arthritis and its Association With Quality of Life, Pain, Fatigue, and Functional and Psychological Status

Disease Activity (Rheumatoid Arthritis Disease Activity Index-5) in Patients With Rheumatoid Arthritis and its Association With Quality of Life, Pain, Fatigue, and Functional and Psychological Status

Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis

Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study

Contact Info

Product

Resources

About